Puma Biotechnology PBYI
NASDAQ PBYI
$9.55 +0.14 (+1.49%)
As of: Sep 4, 2026 · 3:59 PM EDT

Puma Biotechnology (PBYI) EBITDA Margin Growth (3y) (2020 - 2026)

Analysis

Puma Biotechnology (PBYI) EBITDA Margin Growth (3y) (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -204.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 7,045.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -1,934.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 7,261.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 9,003.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -2,649.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 30,461.00
10 Puma Biotechnology 486.99 Mn 393.08 Mn 44.03 Mn 446.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 446.00
Mar 31, 2026 -1,681.00
Dec 31, 2025 742.00
Sep 30, 2025 1,338.00
Jun 30, 2025 -760.00
Mar 31, 2025 1,029.00
Dec 31, 2024 1,028.00
Sep 30, 2024 4,678.00
Jun 30, 2024 2,653.00
Mar 31, 2024 -2,577.00
Dec 31, 2023 4,172.00
Sep 30, 2023 3,920.00
Jun 30, 2023 -114.00
Mar 31, 2023 3,610.00
Dec 31, 2022 2,902.00
Sep 30, 2022 2,983.00
Jun 30, 2022 6,807.00
Mar 31, 2022 -1,157.00
Dec 31, 2021 3,842.00
Sep 30, 2021 -135.00